Semaglutide vs Tirzepatide: STEP 1 Was the Most Important Obesity Trial in a Generation, and SURMOUNT-1 Was Even More Important — The Mechanism, the Numbers, and What Dual GLP-1/GIP Agonism Changes About the Biology
Updated: June 2026semaglutide weight loss · tirzepatide weight loss · Ozempic weight loss · Wegovy weight loss · Mounjaro weight loss · Zepbound weight loss · GLP-1 weight loss · GLP-1 receptor agonist · GLP-1 how it works · GLP-1 mechanism · GLP-1 appetite suppression · GLP-1 gastric emptying · GLP-1 hypothalamus · GLP-1 satiety · GLP-1 insulin · GIP receptor · dual GLP-1 GIP agonist · tirzepatide GIP GLP-1 · GIP mechanism · GIP insulin sensitizer · GIP adipose · STEP 1 trial · STEP 1 semaglutide · STEP 1 Wilding 2021 · semaglutide 2.4mg weekly · Wegovy trial results · semaglutide placebo comparison · STEP 2 3 4 5 trials · STEP 5 semaglutide 2 years · SURMOUNT-1 trial · SURMOUNT-1 tirzepatide · SURMOUNT-1 Jastreboff 2022 · tirzepatide 15mg weight loss · tirzepatide vs semaglutide · tirzepatide head to head · SURPASS-CVOT · SELECT trial · SELECT cardiovascular semaglutide · SELECT MACE semaglutide · GLP-1 heart disease · GLP-1 heart failure · FLOW trial · FLOW kidney semaglutide · semaglutide kidney disease · GLP-1 kidney protection · GLP-1 CKD · GLP-1 beta cell · GLP-1 pancreas · GLP-1 type 2 diabetes · GLP-1 insulin secretion · GLP-1 glucagon suppression · ozempic vs wegovy dose · semaglutide 1mg vs 2.4mg · semaglutide injection · tirzepatide injection · GLP-1 nausea · GLP-1 side effects · GLP-1 muscle loss · GLP-1 lean mass · GLP-1 hair loss · GLP-1 pancreatitis risk · GLP-1 thyroid cancer · medullary thyroid carcinoma GLP-1 · GLP-1 gastroparesis · GLP-1 gastric emptying delay · GLP-1 constipation · semaglutide compound pharmacy · GLP-1 compounding · semaglutide dose escalation · tirzepatide dose escalation · rebound after stopping GLP-1 · weight regain after stopping ozempic · GLP-1 maintenance dose · GLP-1 long term use · surgical weight loss comparison · GLP-1 vs bariatric surgery · GLP-1 BMI eligibility · obesity medication 2024 2025 2026 · best GLP-1 for weight loss · liraglutide Victoza · dulaglutide Trulicity · exenatide Byetta · older GLP-1 vs semaglutide
The approval of semaglutide 2.4mg (Wegovy) for obesity in 2021 represented the first time a pharmacological agent consistently produced weight loss exceeding 10% of body weight in a large, controlled trial. That threshold mattered because the previous generation of obesity drugs — phentermine/topiramate, naltrexone/bupropion, orlistat — produced 5–8% weight loss on average, which is clinically meaningful but often insufficient to produce durable metabolic improvements. Semaglutide's 14.9% average weight loss in STEP 1 crossed into territory that had previously required bariatric surgery to achieve. It raised a question that had been considered purely academic: could a medication approach surgical weight loss outcomes? The answer, which arrived 13 months later with SURMOUNT-1, was yes — tirzepatide 15mg produced 20.9% weight loss, approaching the 25–30% typical of Roux-en-Y gastric bypass.
These are not incremental improvements in a crowded market. They represent a phase transition in obesity pharmacology — the gap between semaglutide and its predecessors is wider than the gap between semaglutide and surgery. Understanding why requires understanding what GLP-1 receptor agonists actually do at the mechanistic level, and why adding GIP agonism (tirzepatide's additional target) appears to amplify the effect further.
−14.9%
STEP 1 body weight with semaglutide 2.4mg (Wilding 2021) — STEP 1 (Semaglutide Treatment Effect in People with Obesity, Trial 1): Wilding et al. 2021 (New England Journal of Medicine); N=1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity); randomized 2:1 to semaglutide 2.4mg subcutaneous weekly or placebo, both with lifestyle intervention; 68-week trial; primary endpoint: percent change in body weight at week 68; results: semaglutide: −14.9% body weight; placebo: −2.4% body weight; net treatment difference: −12.4 percentage points; proportion achieving ≥5% weight loss: 86% (semaglutide) vs 32% (placebo); proportion achieving ≥15% weight loss: 32% (semaglutide) vs 2% (placebo); proportion achieving ≥20% weight loss: 20% vs 1%; secondary metabolic outcomes: waist circumference −13.5cm vs −4.1cm; systolic BP −6.2 vs −1.4 mmHg; HbA1c (non-diabetic participants): significantly reduced; STEP 2 (type 2 diabetes, N=1,210): −9.6% weight; STEP 5 (104 weeks): weight loss maintained at 15.2% at 2 years — no attenuation over time; the 68-week trial design underestimates eventual benefit because the plateau has not been reached by week 68 in most participants
−20.9%
SURMOUNT-1 body weight with tirzepatide 15mg (Jastreboff 2022) — SURMOUNT-1: Jastreboff et al. 2022 (New England Journal of Medicine); N=2,539 adults with BMI ≥30 (or ≥27 with comorbidity); randomized to tirzepatide 5mg, 10mg, 15mg, or placebo; 72-week trial; tirzepatide 15mg results: mean weight reduction −20.9%; proportion achieving ≥5%: 91%; proportion achieving ≥15%: 57%; proportion achieving ≥20%: 36%; proportion achieving ≥25%: 22%; tirzepatide 10mg: −19.5%; tirzepatide 5mg: −15.0%; placebo: −3.1%; this dose-response relationship confirms pharmacological mechanism (not regression to mean or behavioral effect); SURMOUNT-2 (type 2 diabetes, N=938): tirzepatide 15mg → −15.7% weight (note: substantially higher baseline insulin resistance slows weight loss in T2DM); SURMOUNT-4 (re-randomization after open-label lead-in): switching from tirzepatide to placebo at week 36 → weight regain to baseline by week 88 (confirming: the drug must be continued; it does not produce permanent remission by "resetting the setpoint"); SURPASS-CVOT (cardiovascular outcomes trial, N=17,604, results 2024): −14.5% tirzepatide vs −1.8% placebo; 17% reduction in 4-point MACE
GLP-1 + GIP
tirzepatide's dual agonism advantage — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones released from intestinal cells after eating; they both stimulate insulin secretion in a glucose-dependent manner (only when glucose is elevated); key distinction: semaglutide is a selective GLP-1 receptor agonist; tirzepatide activates both GLP-1R and GIPR; the proposed mechanisms of GIP's additive benefit: (1) adipose tissue GIPR: GIP receptors are expressed in adipocytes; GIPR activation improves insulin sensitivity in adipose, potentially enhancing fat mobilization; (2) central GIPR: GIPR is expressed in hypothalamic regions controlling food intake; GIPR agonism enhances the satiety signaling from GLP-1; (3) gastric: dual agonism produces greater gastric emptying delay than GLP-1 alone; (4) tolerance: GIPR agonism may reduce the GI side effects of GLP-1R agonism by modulating visceral afferent sensitization; the initial pharmacological hypothesis (GIP agonism raises GLP-1 efficacy tolerance) appears partially correct: tirzepatide GI side effect rates are comparable to semaglutide despite higher efficacy; importantly: tirzepatide's superiority over semaglutide is ONLY established in indirect comparisons (no head-to-head RCT as of 2026); SURPASS-5 (tirzepatide added to insulin) and indirect network meta-analyses consistently favor tirzepatide; SURMOUNT-5 (N=751): tirzepatide −20.2% vs semaglutide −13.7% (head-to-head, first direct comparison published early 2025)
FLOW
GLP-1 kidney protection — FLOW trial (Perkovic 2024, New England Journal of Medicine): N=3,533 adults with type 2 diabetes and chronic kidney disease (eGFR 20–75); randomized to semaglutide 1mg weekly vs placebo; primary composite: major kidney disease events (sustained ≥40% eGFR decline, dialysis, kidney transplant, or kidney/cardiovascular death); results: semaglutide reduced primary outcome by 24% (HR 0.76; 95% CI 0.66–0.88; p<0.001); the trial was stopped early by the Data Safety Monitoring Board due to overwhelming benefit; secondary: all-cause mortality −20%; cardiovascular events −18%; kidney failure −28%; eGFR decline rate significantly slower; SELECT (Lincoff 2023, NEJM, N=17,604): cardiovascular outcomes trial in non-diabetic adults with obesity and established cardiovascular disease; semaglutide 2.4mg → 20% reduction in MACE (non-fatal MI, non-fatal stroke, cardiovascular death) vs placebo; this SELECT finding is particularly significant: it demonstrates cardiovascular benefit in OBESITY (not diabetes) — the mechanism appears to be independent of glucose control, potentially through direct cardiac GLP-1R effects, inflammation reduction, and weight-mediated hemodynamic improvement; together, SELECT + FLOW establish semaglutide as a pleiotropic cardiovascular/renal drug, not merely a metabolic one
GLP-1 Mechanism Deep Dive: How Weight Loss Actually Happens
GLP-1 is a 30-amino-acid peptide hormone secreted by L-cells in the distal ileum and colon (and to a lesser extent the proximal gut) in response to nutrient ingestion — particularly fat and carbohydrate. Endogenous GLP-1 has a plasma half-life of approximately 1–2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Semaglutide is a modified GLP-1 analog with 94% sequence homology to human GLP-1, with structural modifications (Aib substitution at position 8, C18 fatty diacid chain at Lys26) that resist DPP-4 degradation and enable non-covalent albumin binding — producing a half-life of approximately 7 days, enabling once-weekly dosing. The GLP-1 receptor (GLP-1R) is a class B GPCR (G-protein coupled receptor) that, upon agonist binding, activates adenylyl cyclase → cAMP elevation → PKA activation. It is expressed in the pancreatic beta-cell, hypothalamus, brainstem (area postrema, nucleus tractus solitarius), vagal afferents, heart, kidney, and gastrointestinal tract.
The weight loss mechanism operates through at least four distinct pathways: (1) Gastric emptying delay: GLP-1R activation in the stomach reduces gastric motility, slowing the rate at which ingested food passes into the small intestine; this extends the time of gastric distension (a satiety signal) and blunts postprandial glucose excursions; (2) Hypothalamic satiety: GLP-1R is expressed in the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), and paraventricular nucleus (PVN) — the key appetite-regulating regions; GLP-1R agonism increases POMC/CART neuron activity (anorexigenic) and decreases NPY/AgRP neuron activity (orexigenic); the subjective experience: reduced appetite, earlier satiation, decreased "food noise" (the intrusive preoccupation with food between meals); (3) Brainstem vagal satiety: GLP-1R in the area postrema and NTS integrates peripheral satiety signals (gut distension, cholecystokinin) and amplifies them; this is the nausea mechanism — activation at high doses triggers the same circuits that mediate motion sickness; (4) Reward circuit attenuation: GLP-1R in the ventral tegmental area (VTA) and nucleus accumbens (NAc) modulate dopamine reward signaling; GLP-1R agonism reduces the motivational salience of food cues and palatability — patients consistently report food tastes the same but they stop thinking about it.
Clinical Decision: Semaglutide vs Tirzepatide
Who may prefer semaglutide: established cardiovascular disease (SELECT trial data); CKD (FLOW trial data); insurance coverage advantage (Wegovy prior authorization is more established than Zepbound in many plans); patients who want the most comprehensively studied molecule (semaglutide cardiovascular RCT evidence substantially precedes tirzepatide); those with history of gastroparesis or severe GI motility disorders (tirzepatide's greater gastric emptying delay may worsen).
Who may prefer tirzepatide: higher target weight loss (SURMOUNT-1 20.9% vs STEP 1 14.9%); type 2 diabetes with higher baseline HbA1c (GIP component adds insulin sensitization independent of weight loss); better glycemic control per kg weight lost; comparable or slightly lower GI side effect burden despite higher efficacy; current US price/availability advantage (Zepbound launched 2023, compounded tirzepatide widely available in shortage periods).
Dose escalation (critical): both agents require slow titration to minimize GI side effects; semaglutide 2.4mg: start 0.25mg × 4 weeks → 0.5mg × 4 weeks → 1mg × 4 weeks → 1.7mg × 4 weeks → 2.4mg maintenance; tirzepatide 15mg: start 2.5mg × 4 weeks → 5mg × 4 weeks → 7.5mg × 4 weeks → 10mg × 4 weeks → 12.5mg × 4 weeks → 15mg; most GI side effects occur at initiation and during dose escalation; injecting at bedtime can reduce conscious nausea experience; high-fat meals should be avoided within 2–3 hours of injection.
Comparison: GLP-1 Agents and Their Evidence Base
| Agent | Mechanism | Peak Weight Loss (RCT) | CV Outcomes Trial | Key Limitation |
|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1R agonist | −14.9% (STEP 1) | SELECT: −20% MACE ✅ | Cost; injection; requires continuation |
| Tirzepatide 15mg (Zepbound) | GLP-1R + GIPR dual agonist | −20.9% (SURMOUNT-1) | SURPASS-CVOT: −17% MACE ✅ | Less CV/renal RCT evidence vs semaglutide |
| Liraglutide 3mg (Saxenda) | GLP-1R agonist (daily injection) | −8.4% (SCALE trial) | LEADER (1.8mg T2DM): −13% MACE | Daily injection; less efficacious than newer agents |
| Semaglutide 1mg (Ozempic) | GLP-1R agonist (diabetes dose) | ~−6–8% (SUSTAIN trials) | SUSTAIN-6: −26% MACE ✅ | Not approved for obesity; off-label use |
| Dulaglutide (Trulicity) | GLP-1R agonist (weekly) | ~−3% (AWARD trials) | REWIND: −12% MACE ✅ | Substantially lower weight loss; primarily for T2DM |
CGM for GLP-1 Monitoring →
Metabolic Support →